Ohio Pharmacy Law Complete Practice Test 2025

The classification of drugs as controlled substances involves a system governed by the Controlled Substances Act, which categorizes drugs into schedules based on their potential for abuse, accepted medical use, and safety or dependence issues. Schedule V substances are characterized by a lower potential for abuse relative to other schedules and typically include medications that may contain limited quantities of certain narcotics.

Ezogabine (Potiga) is used in the treatment of epilepsy and is considered to have a lower potential for abuse, often falling under the Schedule V category due to its therapeutic uses and reduced risk when used as directed. Lacosamide (Vimpat), while primarily utilized for seizure management, does not have a high abuse potential, placing it in the Schedule V classification as well. Pyrovalerone (Centroton), a stimulant with limited use due to its design as a therapeutic agent, is similarly classified in Schedule V based on its properties and recognized low risk of addiction compared to other drugs.

Considering these factors, all three drugs — Ezogabine, Lacosamide, and Pyrovalerone — can correctly be identified as Schedule V controlled substances, as they fit the criteria set forth for this category. This collective classification signifies that they are recognized for their medical utility